FDA Seeks to Remove Opioid From Market
The FDA has asked Endo International to stop selling its opioid, Opana ER. According to Bloomberg, the drug has become a favorite among addicts even after the company reformulated it to try to prevent abuse. The FDA usually does not order drugs off the market—the agency asks a company to pull a drug voluntarily, which the company typically does. The move marks a shift in how the FDA will review drugs on the market under new commissioner Scott Gottlieb, MD.
Republican Calls to Keep Paying Cost-Sharing Subsidies
Kevin Brady (R-Texas), the chair of the House Ways and Means Committee, is calling for the government to help stabilize insurance markets. Brady said that the government should keep paying the cost-sharing subsidies that help low-income Americans afford insurance under the Affordable Care Act (ACA), reported the Associated Press. As of now, there has been a lot of uncertainty regarding those payments and whether or not the Trump administration will continue to pay them. This uncertainty has led to some insurers leaving ACA markets.
GOP Senators Push for Short-Term Insurance Plans
A group of senators have asked HHS to allow short-term insurance plans to be sold. The Hill reported that such a change would reverse a rule set in place by the Obama administration. Short-term insurance plans are generally less comprehensive in their coverage, but they typically cost less, as a result. The 14 senators are pushing to allow these plans since some counties are now slated to have zero ACA plans available in 2018.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More